SCHEMBL3479697

SCHEMBL3479697

CN1CCN(c2ccc(F)c(F)c2)c2ccc(Br)cc2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
BACE1 P56817 1/20 0.35
SRD5A1 P18405 1/20 0.35
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
RECQL P46063 1/20 0.33
PTK2B Q14289 1/20 0.33
APP P05067 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
ROCK1 Q13464 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3236889 0.86 ALDH1A1 (0.42) SCN9AMEN1KMT2ASRD5A1ALDH1A1
SCHEMBL3479611 0.86 ALDH1A1 (0.46) SCN9AMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3479739 0.85 GAA (0.46) SCN9AMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3223749 0.84 POLB (0.42) SCN9AKMT2ASRD5A1ALDH1A1L3MBTL1
SCHEMBL3479627 0.84 ALDH1A1 (0.39) SCN9ASRD5A1ALDH1A1L3MBTL1SLC6A2
SCHEMBL3239788 0.82 SLC6A2 (0.47) SCN9AMEN1KMT2AALDH1A1SLC6A2
SCHEMBL3224762 0.82 SLC6A2 (0.48) SRD5A1L3MBTL1SLC6A2SLC6A4SLC6A3
SCHEMBL3479762 0.82 SCN9A (0.49) SCN9AMEN1KMT2AALDH1A1KDM4E
SCHEMBL3479751 0.82 SLC6A2 (0.48) KMT2AALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL3230403 0.81 ALDH1A1 (0.39) SCN9AMEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885MEN1 1276/4885KMT2A 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.